167 related articles for article (PubMed ID: 32336065)
1. [Analysis of Clinical Characteristics and Driver Genes in 405 Patients with Lung Cancer Complicated with Tuberculosis].
Hu Y; Yang X; Nie L; Zhao D; An J; Li B
Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):337-342. PubMed ID: 32336065
[TBL] [Abstract][Full Text] [Related]
2. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
3. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
4. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
5. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
6. [Clinical features of 54 cases of lung adenocarcinomas with c-ROS oncogene 1 fusion].
Cao H; Zheng J; Zhao J; Guo XJ; Zhou JY; Ding W; Zhou JY
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Feb; 43(2):120-125. PubMed ID: 32062881
[No Abstract] [Full Text] [Related]
7. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
9. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
[TBL] [Abstract][Full Text] [Related]
10. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
Gow CH; Wu SG; Chang YL; Shih JY
Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
12. EGFR mutations and ROS1 and ALK rearrangements in a large series of non-small cell lung cancer in South India.
Tarigopula A; Ramasubban G; Chandrashekar V; Govindasami P; Chandran C
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1288. PubMed ID: 32881404
[TBL] [Abstract][Full Text] [Related]
13. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
[TBL] [Abstract][Full Text] [Related]
14. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
Ju L; Han M; Zhao C; Li X
Lung Cancer; 2016 May; 95():94-7. PubMed ID: 27040858
[TBL] [Abstract][Full Text] [Related]
15. [Association between the ALK Gene Status and the Efficacy of First-line
Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma].
Chen M; Cao H; Ji Y; Mao Y; Shen S; Li X
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):732-736. PubMed ID: 29167001
[TBL] [Abstract][Full Text] [Related]
16. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
[TBL] [Abstract][Full Text] [Related]
17. Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma: A Multicentric Study.
Yilmaz S; Demirci NY; Metintas S; Zamani A; Karadag M; Guçlu OA; Kabalak PA; Yilmaz U; Ak G; Kizilgoz D; Ozturk A; Yilmaz U; Batum O; Kavas M; Serifoglu I; Unsal M; Komurcuoglu BE; Cengiz TI; Ulubay G; Ozdemirel TS; Ozyurek BA; Kavurgaci S; Alizoroglu D; Celik P; Erdogan Y; In E; Aksoy A; Altin S; Gunluoglu G; Metintas M
J Occup Environ Med; 2021 Mar; 63(3):238-243. PubMed ID: 33399308
[TBL] [Abstract][Full Text] [Related]
18. Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations.
Wang H; Wang Z; Zhang G; Zhang M; Zhang X; Li H; Zheng X; Ma Z
Cancer Med; 2020 Jan; 9(2):487-495. PubMed ID: 31769228
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
Chen LF; Chen XY; Yu XB
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
[TBL] [Abstract][Full Text] [Related]
20. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
